Sign up to save your podcasts
Or
Share Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.
View all episodes
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Neil M. Iyengar, MD
Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.